About the journal
Cancer Cell is a journal published by Cell Press in Netherlands. It is listed in MEDLINE and PUBMED according to the sources read. Declared publication charge: 9,080 USD. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Cell Press
- ISSN
- 1878-3686 · 1535-6108
- Country
- Netherlands
- Access
- Not open access / not declared
- Declared publication charge
- 9,080 USD
- Official website
- https://www.sciencedirect.com/journal/cancer-cell
Index listings
- MEDLINE · 2002-01-01
- PUBMED · 2008-07-08
- Indexing
- MEDLINE · PUBMED
- APC
- 9,080 USD
- Declared review time (DOAJ)
- —
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
4243
Last recorded publication year
2026
h-index
484
i10-index
3395
From OpenAlex open data (CC0).
Editorial & policy4
- Observed digital preservation (Keepers registry)— snapshot 2026-09-21
- CLOCKSSPortico
- Norwegian register (HK-dir)— 2027
- Level 2 — top tier (~20% of the field's channels)
- Open references deposited at Crossref
- 92%
- ORCID iDs in current deposits
- 47%
- Deposits licence metadata at Crossref
- ✓
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101130617
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Cancer-related Molecular Pathways
Show all subjects (50)
- CAR-T cell therapy research
- CAR-T cell therapy research
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Immunotherapy and Immune Responses
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- Immune cells in cancer
- Immune cells in cancer
- Ubiquitin and proteasome pathways
- Ubiquitin and proteasome pathways
- Acute Myeloid Leukemia Research
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Immune Cell Function and Interaction
- RNA modifications and cancer
- RNA modifications and cancer
- Glioma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Protein Degradation and Inhibitors
- PI3K/AKT/mTOR signaling in cancer
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related gene regulation
- Cancer-related gene regulation
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Single-cell and spatial transcriptomics
- Single-cell and spatial transcriptomics
- Angiogenesis and VEGF in Cancer
- Angiogenesis and VEGF in Cancer
- Microtubule and mitosis dynamics
- Microtubule and mitosis dynamics
- Histone Deacetylase Inhibitors Research
- Histone Deacetylase Inhibitors Research
- Cancer Research and Treatments
- Cancer Research and Treatments
- Melanoma and MAPK Pathways
- Melanoma and MAPK Pathways
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ